Neuralink Corp. is an American neurotechnology company developing implantable brain-computer interfaces (BCIs). Founded in 2016 by Elon Musk and a team of eight scientists and engineers, the company seeks to create devices that can read and write neural signals, with applications ranging from treating brain and spinal injuries to enabling human enhancement. Neuralink is headquartered in Fremont, California, and has pursued ambitious timelines for human trials, receiving approval for such trials in the United States in 2023.
The company's technology involves ultra-thin probes inserted into the brain, a surgical robot for implantation, and high-density electronics for signal processing. Neuralink has demonstrated its system in animal models and, in January 2024, announced the first human implant. The company has also faced scrutiny over its animal testing practices and internal management challenges, while continuing to develop new applications such as a visual prosthesis called Blindsight.
Founding and Early History
Neuralink was founded in 2016 by Elon Musk and eight scientists and engineers: Max Hodak, Benjamin Rapoport, Dongjin Seo, Paul Merolla, Philip Sabes, Tim Gardner, Tim Hanson, and Vanessa Tolosa. The initial team included experts in neuroscience, biochemistry, and robotics. In January 2017, Musk's proxies approached Pedram Mohseni and Randolph Nudo, who owned the rights to the name "NeuraLink" and a prototype on which the company based its work. Neuralink was first publicly reported in March 2017.
In April 2017, Neuralink announced its short-term aim to develop devices for treating serious brain diseases, with the eventual goal of human enhancement, sometimes called transhumanism. Musk cited the concept of "neural lace" from Iain M. Banks' The Culture novels as an inspiration, defining it as a "digital layer above the cortex" that could be implanted through a vein or artery. He stated that the long-term goal was to achieve "symbiosis with artificial intelligence", which he perceives as an existential threat to humanity if left unchecked. Musk described the device as potentially enabling a "saved game situation" where a person could resume and upload their last state, and address brain or spinal injuries by compensating for lost capacity with a chip.
Leadership and Internal Dynamics
Jared Birchall, head of Musk's family office, was listed as Neuralink's CEO, CFO, and president in 2018. As of September 2018, Musk was the majority owner but did not hold an executive position. Co-founder Benjamin Rapoport left Neuralink in 2018, citing safety concerns as a major influence on his decision. Rapoport subsequently founded Precision Neuroscience, which emphasizes surface electrodes rather than the penetrating electrodes used by Neuralink, to address potential brain damage and other safety issues.
By August 2020, only three of the eight founding scientists remained at the company, according to a report by Stat News. The article described "years of internal conflict in which rushed timelines have clashed with the slow and incremental pace of science." In May 2021, co-founder and president Max Hodak announced he no longer worked with the company. Only two of the eight co-founders remained as of January 2022. In February 2024, Musk changed Neuralink's state of incorporation from Delaware to Nevada after a Delaware Chancery Court judge voided Musk's $55 billion pay package at Tesla. In April 2025, Neuralink faced criticism for falsely labeling itself a "small disadvantaged business" in a federal filing with the U.S. Small Business Administration.
Funding and Facilities
By 2019, Neuralink had received $158 million in funding, with $100 million coming from Musk, and employed 90 people. The company initially operated in San Francisco's Mission District, sharing the Pioneer building with OpenAI, another company Musk co-founded. As of 2022, Neuralink's headquarters were located in Fremont, California. The company has also announced plans to build a three-story facility with office and manufacturing space in Del Valle, Texas, about 10 miles east of Gigafactory Texas, Tesla's headquarters and manufacturing plant.
Technology and Development
In 2018, Gizmodo reported that Neuralink "remained highly secretive about its work." Public records showed the company had sought to open an animal testing facility in San Francisco, but it subsequently began research at the University of California, Davis. In 2019, during a live presentation at the California Academy of Sciences, the Neuralink team revealed its first prototype: a system involving ultra-thin probes inserted into the brain, a neurosurgical robot for implantation, and a high-density electronic system for processing neural information. The technology is based on work developed at the University of California, San Francisco and the University of California, Berkeley.
Probes
The probes are made mostly of polyimide, a biocompatible material, with a thin gold or platinum conductor. They are inserted into the brain through an automated process performed by a surgical robot. Each probe consists of wires containing electrodes that locate electrical signals in the brain, along with a sensory area where the wire interacts with an electronic system for signal amplification and acquisition. Each probe contains 48 or 96 wires, each with 32 independent electrodes, yielding up to 3,072 electrodes per formation.
Surgical Robot
Neuralink has engineered a surgical robot capable of rapidly inserting many flexible probes into the brain. The robot is designed to avoid blood vessels and perform the delicate procedure with precision, addressing one of the key challenges of implanting thin, flexible threads without causing tissue damage.
Animal Testing and Controversies
The company has faced criticism for the large number of primates euthanized after medical trials. Veterinary records allegedly showed complications with surgically implanted electrodes, raising concerns about animal welfare and the safety of the technology. Neuralink has not publicly detailed the full extent of its animal testing practices, but the criticism has been a recurring issue in media coverage.
Human Trials and Milestones
Neuralink initially anticipated starting human experiments in 2020, but later moved that timeline to 2023. As of May 2023, the company had received approval for human trials in the United States. On January 29, 2024, Musk announced that Neuralink had successfully implanted a device in a human patient, who was later identified as Noland Arbaugh. The patient was reported to be recovering after the procedure.
In August and September 2025, Toronto's University Health Network performed Canada's first Neuralink brain implant surgeries on two patients with cervical spinal cord injuries, marking the first such procedures outside the United States.
Blindsight and Future Applications
In September 2024, Neuralink announced its latest development effort, Blindsight, which aims to enable blind people whose visual cortex is undamaged to regain some level of vision. The development received "breakthrough" status from the U.S. federal government, which is expected to accelerate its development timeline. This application builds on the company's broader goal of addressing neurological deficits through implantable devices, with potential future applications in areas such as memory enhancement and communication for paralyzed individuals.
Broader Context and Artificial Intelligence
Neuralink's work sits at the intersection of neurotechnology and artificial intelligence. The company's long-term vision of achieving symbiosis with AI reflects broader discussions in the field about human-machine integration. While Neuralink is not directly involved in developing large language models or generative AI systems, its goal of creating a high-bandwidth interface between the brain and computers could potentially complement advances in machine learning and neural networks. The company's approach differs from that of organizations like OpenAI or Google DeepMind, which focus on software-based AI, by emphasizing hardware that connects directly to biological tissue.
Reception and Scientific Assessment
Scientists have acknowledged that Neuralink's engineering advances, such as making implants wireless and increasing electrode counts, represent progress in the field of brain-computer interfaces. However, similar technology has existed since 2002, when a research group demonstrated a monkey moving a computer cursor with neural signals. The company's rapid timelines have drawn both praise for ambition and criticism for potentially compromising scientific rigor. As of 2025, Neuralink continues to operate as a private company, with Musk remaining a central figure in its public profile and strategic direction.